Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Tryptophan metabolism by intestinal microbiota: Implications for inflammatory bowel disease.
EF 2019-20
Résumé
"Inflammatory bowel diseases (IBD) are chronic relapsing diseases characterized by severe inflammation in the digestive tract. Our gut is exposed to a vast number of bacteria and microorganisms, called microbiota, which in combination with food components, are important for maintaining health. There is growing evidence suggesting that when food-bacterial interactions are broken, conditions like IBD can develop. However, the factors underlying this breakdown are unclear. I propose to study how certain bacteria from the human gut metabolise dietary proteins, like tryptophan, to produce molecules which activate a receptor called the ""aryl hydrocarbon receptor"" (AhR). Recent studies have shown that AhR function is abnormal in patients with IBD, who also have an altered microbiota and impaired production of compounds which activate AhR (""agonists""). What is not known is which bacteria are responsible for the defective production of AhR agonists from foods, and the metabolic pathways involved. I will isolate and study bacteria involved in tryptophan metabolism from patients with IBD and from healthy controls. I will study their tryptophan metabolism in vitro and in vivo using germ-free mice colonized with selected bacteria. Finally, I will use models of colitis to study the capacity of these bacteria to activate AhR and decrease disease severity. About 1% of the Canadian population is expected to have IBD by 2030. Additionally, current therapies to induce and maintain remission are dominated by drugs that often lose effectiveness over time, suggesting the need for complementary therapies. Our long-term goal is to develop combinations of bacteria which act on dietary tryptophan to restore AhR function and prevent and treat IBD."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429053
Name
Rondeau Liam E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Tryptophan metabolism by intestinal microbiota: Implications for inflammatory bowel disease.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Colitis; Diet; Inflammation; Inflammatory Bowel Disease; Microbiota; Probiotic
Abstract
"Inflammatory bowel diseases (IBD) are chronic relapsing diseases characterized by severe inflammation in the digestive tract. Our gut is exposed to a vast number of bacteria and microorganisms, called microbiota, which in combination with food components, are important for maintaining health. There is growing evidence suggesting that when food-bacterial interactions are broken, conditions like IBD can develop. However, the factors underlying this breakdown are unclear. I propose to study how certain bacteria from the human gut metabolise dietary proteins, like tryptophan, to produce molecules which activate a receptor called the ""aryl hydrocarbon receptor"" (AhR). Recent studies have shown that AhR function is abnormal in patients with IBD, who also have an altered microbiota and impaired production of compounds which activate AhR (""agonists""). What is not known is which bacteria are responsible for the defective production of AhR agonists from foods, and the metabolic pathways involved. I will isolate and study bacteria involved in tryptophan metabolism from patients with IBD and from healthy controls. I will study their tryptophan metabolism in vitro and in vivo using germ-free mice colonized with selected bacteria. Finally, I will use models of colitis to study the capacity of these bacteria to activate AhR and decrease disease severity. About 1% of the Canadian population is expected to have IBD by 2030. Additionally, current therapies to induce and maintain remission are dominated by drugs that often lose effectiveness over time, suggesting the need for complementary therapies. Our long-term goal is to develop combinations of bacteria which act on dietary tryptophan to restore AhR function and prevent and treat IBD."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rondeau, Liam E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~